High levels of pipeline activity are being observed in Vaso-Occlusive Crisis Associated With Sickle Cell Disease treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including AstraZeneca Plc, bluebird bio Inc, Global Blood Therapeutics Inc, Hillhurst Biopharmaceuticals Inc, Imara Inc and others.
A Significant contribution to the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline included 12 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Vaso-Occlusive Crisis Associated With Sickle Cell Disease condition and increased access to investments is encouraging growth of Vaso-Occlusive Crisis Associated With Sickle Cell Disease drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Vaso-Occlusive Crisis Associated With Sickle Cell Disease drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Vaso-Occlusive Crisis Associated With Sickle Cell Disease. Further, orphan drug status, fast track designation, grants awarded and other special status for Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline and formulate effective research and development strategies.
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline candidates- - Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease drugs
- Late phase: Phase 3 and in-approval Vaso-Occlusive Crisis Associated With Sickle Cell Disease drugs
Companies involved in the Pipeline- - Company overview
- Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutic treatment activities
Details for each Vaso-Occlusive Crisis Associated With Sickle Cell Disease drug candidate- - Snapshot
- Drug Name
- Alternative Names
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
Other details - Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
Recent Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Our reports have been used by over 10K customers, including:
Intravenous (IV) solutions are a complete mix of essential nutrients which are intended to replenish fluid losses, treat electrolyte imbalances and maintain fluid balance in intravenous therapy. They also provide required nutrients to the patients suffering from diabetes, cancer and other diseases. Intravenous solutions...
646 pages •
By Global Industry Analysts
• May 2021
Global Laparoscopic Devices Market to Reach $15.8 Billion by 2026
Laparoscopy is a form of minimally invasive surgery used in studying organs in pelvic and abdominal area of the body. The introduction of laparoscopic techniques revolutionized the surgical world through a gradual...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
120 pages •
By Infiniti Research Limited
• Mar 2021
Global Pathology Instruments Market 2021-2025 The analyst has been monitoring the pathology instruments market and it is poised to grow by $ 1.23 bn during 2021-2025 progressing at a CAGR of 6% during the forecast period. Our report on pathology instruments market provides a holistic analysis, market size and forecast,...
Melanoma - Epidemiology Forecast to 2029
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
278 pages •
By Global Industry Analysts
• Apr 2021
- Global Anatomic Pathology Market to Reach $26.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Anatomic Pathology estimated at US$18.7 Billion in the year 2020, is projected to reach a revised size of US$26.3 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027....
185 pages •
By Global Industry Analysts
• Apr 2021
- Global Pathology Instruments Market to Reach $4.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Pathology Instruments estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 5.2% over the analysis period 2020-2027....
The Global Magnetic Beads Market size is expected to reach $2 billion by 2026, rising at a market growth of 12.7% CAGR during the forecast period. Magnetic beads refer to a tool, which is made up of small particles of iron oxides like magnetite that provide superparamagnetic properties to these beads. They do not attract one another when they...
Melanoma - Global Drug Forecast and Market Analysis to 2029
Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body.Although melanoma has high survivability, it remains a significant health...
Health Care Provider
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.